Implantica Gains Enthusiastic Reception for RefluxStop®
Implantica AG (publ.), a pioneering medtech company, proudly announces overwhelming support from numerous physicians in the U.S. who are eager to adopt its innovative product, RefluxStop®, pending the required FDA clearance. This enthusiasm is largely attributed to the outstanding outcomes observed over five years in CE-mark studies, coupled with successful experiences shared by multiple healthcare centers.
A Highlighted Presence at the AFS Meeting
During the recent American Foregut Society (AFS) Annual Meeting, attended by over 600 leading practitioners in the fields of anti-reflux surgery and gastroenterology, RefluxStop® was a central topic of conversation. This significant gathering provided a platform for discussion on advancements in the treatment of foregut diseases and showcased the promising discussions surrounding RefluxStop®.
Prospects of FDA Approval
Currently, Implantica is excelling in its efforts to expedite the FDA approval process to successfully introduce RefluxStop® into the U.S. market. The company anticipates filing the second module of a three-part PMA submission soon, accelerating the path to availability for American patients.
Expert Insights and Data Presentation
The meeting featured an informative panel focusing on RefluxStop®, led by Dr. John Lipham, a distinguished professor at the Keck School of Medicine. He unveiled critical long-term data affirming the outcomes of the CE-mark study conducted over five years, which further corroborated prior results published after one and four years. Real-world data from numerous patients in Europe including significant findings from Switzerland and Germany were also highlighted.
Innovative Features of RefluxStop®
Dr. Lipham emphasized, "The CE mark data indicates highly consistent results, which is remarkable. It's fascinating to observe how the mechanism of action of RefluxStop® aligns with the AFS white paper on anti-reflux barriers released in late 2022. Addressing all three key components of the anti-reflux barrier effectively tackles acid reflux, illustrating RefluxStop's innovative approach and distinctiveness from traditional options. I am hopeful that this beneficial technique will be available to U.S. patients soon, pending FDA clearance."
Gastroenterology Perspectives on long-term Outcomes
Dr. Felice Schnoll-Sussman from Weill Cornell Medicine and the AFS president provided valuable insights, stating that the long-term outcomes observed after utilizing RefluxStop® could present a viable solution for patients, especially those who may not be suitable candidates for conventional surgical methods. The lower incidence of typical post-surgical complications amplifies the excitement surrounding this innovative procedure.
The Urgency for Innovation in GERD Treatment
Dr. Peter Forsell, CEO of Implantica, expressed gratitude towards the support shown at the AFS meeting, emphasizing the pressing need for fresh surgical interventions catering to GERD sufferers in the U.S., where it is estimated that 20% of adults experience this condition. "We are optimistic that RefluxStop® can bridge this substantial treatment gap in GERD management for millions, once we await FDA approval," he stated, signifying the enthusiasm of the innovation.
Diverse Panel of Expert Commentary
A lineup of esteemed panelists offered additional perspectives, including Dr. Reginald Bell, Past-President of the AFS, and Prof. Dr. Peter Kahrilas from Northwestern University, among others. Their combined expertise served to bolster the credibility and scientific foundation of the discussions surrounding RefluxStop®, showcasing a collaborative effort to address GERD treatment solutions.
About Implantica and RefluxStop®
Implantica focuses on integrating advanced technology with clinical practices. Their leading product, RefluxStop®, is designed to prevent gastroesophageal reflux and holds potential for significant shifts in treatment approaches. The RefluxStop® mechanism uniquely reconstructs the anti-reflux barrier without encircling vital pathways, differentiating it from conventional surgical options that can produce various complications.
Implantica’s Commitment and Future Directions
As Implantica transitions towards FDA approval, their commitment lies in innovatively enhancing patient care for those dealing with conditions like GERD. The future for RefluxStop® looks promising, with scientific backing paving the way for an accessible and effective treatment option for many.
Frequently Asked Questions
What is RefluxStop® and how does it work?
RefluxStop® is an innovative implant designed to prevent gastroesophageal reflux by reconstructing the anti-reflux barrier without encircling the food passageway, thereby reducing complications associated with traditional procedures.
Why is the American Foregut Society meeting significant for Implantica?
The AFS meeting is an essential platform for sharing clinical data and engaging with specialists, fostering support and interest for RefluxStop® ahead of its U.S. launch.
What are the expected benefits of RefluxStop® for GERD patients?
Patients are expected to experience fewer complications and improved quality of life, as RefluxStop® addresses GERD without the typical side effects related to traditional surgical options.
When can we expect to see RefluxStop® available in the U.S.?
Implantica anticipates filing for FDA approval shortly, with expectations for RefluxStop® to enter the U.S. market once the approval process is completed successfully.
How does Implantica plan to support RefluxStop® post-launch?
Implantica aims to provide comprehensive training for healthcare providers and ongoing support to ensure successful implementation and patient outcomes following the launch.
